Fig. 3: Ethyl cinnamate (ECi)-based iCO clearing and ready for the HCS system using iCOs. | Nature Communications

Fig. 3: Ethyl cinnamate (ECi)-based iCO clearing and ready for the HCS system using iCOs.

From: A logical network-based drug-screening platform for Alzheimer’s disease representing pathological features of human brain organoids

Fig. 3

a ECi-based iCO clearing and HCS imaging workflow. b Transparency of iCOs after the ECi tissue clearing. c, d Representative 3D organoid imaging using HCS system and 3D imaging technique after ECi-based tissue clearing procedure. Aβ (red) and p-tau (green) antibodies were used (scale bar, 1 mm) (p-value criteria: #p < 0.1, *p < 0.05, **p < 0.01, and ***p < 0.001; for PiB− iCOs and PiB+ iCOs, ***p = 0.0007 for Aβ, *p = 0.0474 for p-tau; for E4iso iCOs and E3par iCOs, *p = 0.0135 for Aβ, #p = 0.0841 for p-tau; two-sided p-values; unpaired t-test; 10-20 iCOs were used for each group). White arrows, position of Aβ aggregates in the iCOs; White scale bar, 0.5 mm. PiB Pittsburgh compound B, Aβ beta-amyloid, p-tau phosphorylated tau, IntDen integrated density.

Back to article page